Kastrationsresistentes Prostatakarzinom: [177Lu]Lu-PSMA-617 versus Cabazitaxel

[Article in German]

No authors listed

Comment

[Article in German]

No authors listed. Aktuelle Urol. 2023 Aug.

. 2023 Aug;54(4):269.

doi: 10.1055/a-2017-7363. Epub 2023 Aug 4.

No abstract available

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

[¹⁷⁷Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.
Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, Pattison DA, Tan TH, Kirkwood ID, Ng S, Francis RJ, Gedye C, Rutherford NK, Weickhardt A, Scott AM, Lee ST, Kwan EM, Azad AA, Ramdave S, Redfern AD, Macdonald W, Guminski A, Hsiao E, Chua W, Lin P, Zhang AY, McJannett MM, Stockler MR, Violet JA, Williams SG, Martin AJ, Davis ID; TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Hofman MS, et al. Lancet. 2021 Feb 27;397(10276):797-804. doi: 10.1016/S0140-6736(21)00237-3. Epub 2021 Feb 11. Lancet. 2021. PMID: 33581798 Clinical Trial.
Kommentar zu Kastrationsresistentes Prostatakarzinom: [177Lu]Lu-PSMA-617 versus Cabazitaxel.
[No authors listed] [No authors listed] Aktuelle Urol. 2023 Aug;54(4):269-270. doi: 10.1055/a-2084-8214. Epub 2023 Aug 4. Aktuelle Urol. 2023. PMID: 37541233 German. No abstract available.